RGNX — REGENXBIO Inc.

—
Nasdaq · Health Care · Biotechnology · CIK 1590877 ·
Last close
$7.24
Market Cap
$478.73M
52W High
$16.19
52W Low
$5.45
ADV30
1,305,796
Next earnings
2026-11-05

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 9,162,000 8,021,000 -73,560,000 -40,738,000 466,040,000 95,795,000 317,998,000
Jun 2026 108,019,000 106,977,000 29,263,000 22,709,000 386,618,000 36,487,000 314,853,000
Mar 2026 6,393,000 -4,681,000 -83,362,000 -90,051,000 341,894,000 15,229,000 320,812,000
Dec 2025 30,337,000 24,409,000 -57,636,000 -67,149,000 453,032,000 34,466,000 350,299,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-152,105,000
Investing CF
$87,898,000
Financing CF
$101,200,000
CapEx
$-2,697,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.21
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$-1,234,107,000
Inventory
—
Receivables
$9,497,000
ST Investments
$155,181,000
EBIT TTM
$-138,980,000
Pretax Income TTM
$-175,229,000
Interest Exp TTM
$36,249,000
Analysts
11

Yahoo Snapshot (yfinance, live)

Total Revenue
$153,911,008
EBITDA
$-170,296,992
Free Cash Flow
$-128,852,000
Enterprise Value
$505,102,208
Total Cash
$250,976,000
Total Debt
$252,224,000
Shares Out
66,122,600
Trailing EPS
$-3.20
Book Value
$2.24
ROE
-113.2%
ROA
-23.4%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 170,441,000 -161,198,000 -193,878,000 453,032,000 350,299,000 102,733,000 -123,963,000
Dec 2024 83,328,000 -231,245,000 -227,102,000 465,989,000 206,338,000 259,651,000 -173,125,000
Dec 2023 90,242,000 -268,128,000 -263,494,000 573,970,000 262,228,000 311,742,000 -218,407,000
Dec 2022 112,724,000 -262,876,000 -280,321,000 833,268,000 317,073,000 516,195,000 -207,488,000

TTM Snapshot

Revenues TTM
$174,482,000
NetIncome TTM
$-196,432,000
OpCashFlow TTM
—
Assets (Latest)
$386,618,000
Forward EPS
$-3.06

Max Pain — expiry 2027-04-16 (volume-derived — Yahoo OI feed degraded)

max pain strike: $8.00 · spot: $7.26 · call volume: 61 · put volume: 306
Expected Move to 2027-04-16: ±$4.54 (62.53%) — implied range $2.72 – $11.80 · ATM straddle on $7.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
FENC FENNEC PHARMACEUTICALS INC. $479.44M $13.58 —
DNA Ginkgo Bioworks Holdings, Inc. $448.81M $8.32 —
ENTX Entera Bio Ltd. $521.77M $3.00 —
ETRA Electra Therapeutics, Inc. $524.10M $8.35 —
VALN Valneva SE $527.69M $5.57 —

News headlines (Yahoo Finance, 1h cache)

Regenxbio Inc (RGNX) (Q3 2026) Earnings Call Highlights: Dual Gene Therapy Catalysts Near ...
2026-11-07 07:33 · Yahoo
REGENXBIO Q3 Earnings Call Highlights
2026-11-06 18:15 · Yahoo
REGENXBIO (RGNX) Q3 2026 Earnings Call Transcript
2026-11-05 19:33 · Yahoo
Regenxbio (RGNX) Reports Q3 Loss, Misses Revenue Estimates
2026-11-05 13:35 · Yahoo
Regenxbio: Q3 Earnings Snapshot
2026-11-05 12:32 · Yahoo
REGENXBIO Reports Third Quarter 2026 Financial Results and Operational Highlights
2026-11-05 12:05 · Yahoo
Wall Street Analysts See a 214.55% Upside in Regenxbio (RGNX): Can the Stock Really Move This High?
2026-11-04 13:55 · Yahoo
REGENXBIO to Participate in Stifel 2026 Healthcare Conference
2026-11-03 12:05 · Yahoo
Regenxbio (RGNX) Expected to Beat Earnings Estimates: Should You Buy?
2026-10-29 13:00 · Yahoo
REGENXBIO to Host Conference Call on November 5 to Discuss Third Quarter 2026 Financial Results and Operational Highlights
2026-10-29 11:05 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.